

BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

Azizulah Kamali, M.D.

Physician's & Surgeon's
Certificate No A 40135

Respondent.

Case No. 800-2018-042334


DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on November 19, 2021.

IT IS SO ORDERED October 21, 2021.

MEDICAL BOARD OF CALIFORNIA



Laurie Rose Lubiano, J.D. Chair
Panel A

1 ROB BONTA
Attorney General of California
2 STEVEN D. MUNI
Supervising Deputy Attorney General
3 JOHN S. GATSCHET
Deputy Attorney General
4 State Bar No. 244388
California Department of Justice
5 1300 I Street, Suite 125
P.O. Box 944255
6 Sacramento, CA 94244-2550
Telephone: (916) 210-7546
7 Facsimile: (916) 327-2247

8 *Attorneys for Complainant*

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

AZIZULAH KAMALI, M.D.
1947 N. California St., Ste. A
Stockton, CA 95204-6029

Physician's and Surgeon's Certificate No. A 40135,

Respondent.

Case No. 800-2018-042334

OAH No. 2021020014

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER**

IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-entitled proceedings that the following matters are true:

PARTIES

1. William Prasifka ("Complainant") is the Executive Director of the Medical Board of California ("Board"). He brought this action solely in his official capacity and is represented in this matter by Rob Bonta, Attorney General of the State of California, by John S. Gatschet, Deputy Attorney General.

///
///

1 14. The parties understand and agree that Portable Document Format (PDF) and facsimile
2 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile
3 signatures thereto, shall have the same force and effect as the originals.

4 15. In consideration of the foregoing admissions and stipulations, the parties agree that
5 the Board may, without further notice or opportunity to be heard by the Respondent, issue and
6 enter the following Disciplinary Order:

7 **DISCIPLINARY ORDER**

8 **A. PUBLIC REPRIMAND**

9 **IT IS HEREBY ORDERED THAT** the Physician's and Surgeon's Certificate No. 40135
10 issued to Respondent Azizulah Kamali, M.D., shall be and is hereby publically reprimanded
11 pursuant to California Business and Professions Code section 2227, subdivision (a)(4). This
12 Public Reprimand, which is issued in connection with Accusation No. 800-2018-042334, is as
13 follows:

14 "Between November 1, 2016, and April 16, 2018, while treating Patients 1 and 2, you failed
15 to properly document their pain management care as you prescribed controlled substances to them
16 as more fully described in Accusation No. 800-2018-042334."

17 **B. PRESCRIBING PRACTICES COURSE**

18 Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a
19 course in prescribing practices approved in advance by the Board or its designee. Respondent
20 shall provide the approved course provider with any information and documents that the approved
21 course provider may deem pertinent. Respondent shall participate in and successfully complete
22 the classroom component of the course not later than six (6) months after Respondent's initial
23 enrollment. Respondent shall successfully complete any other component of the course within
24 one (1) year of enrollment. The prescribing practices course shall be at Respondent's expense
25 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of
26 licensure.

27 A prescribing practices course taken after the acts that gave rise to the charges in the
28 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board

1 or its designee, be accepted towards the fulfillment of this condition if the course would have
2 been approved by the Board or its designee had the course been taken after the effective date of
3 this Decision.

4 Respondent shall successfully complete all coursework and provide proof of completion of
5 the Prescribing Practices Course to the Board within one year of the effective date of the Decision
6 and Order. This condition shall be monitored by the Probation Department.

7 **C. MEDICAL RECORD KEEPING COURSE**

8 Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a
9 course in medical record keeping approved in advance by the Board or its designee. Respondent
10 shall provide the approved course provider with any information and documents that the approved
11 course provider may deem pertinent. Respondent shall participate in and successfully complete
12 the classroom component of the course not later than six (6) months after Respondent's initial
13 enrollment. Respondent shall successfully complete any other component of the course within
14 one (1) year of enrollment. The medical record keeping course shall be at Respondent's expense
15 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of
16 licensure.

17 A medical record keeping course taken after the acts that gave rise to the charges in the
18 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
19 or its designee, be accepted towards the fulfillment of this condition if the course would have
20 been approved by the Board or its designee had the course been taken after the effective date of
21 this Decision.

22 Respondent shall successfully complete all coursework and provide proof of completion of
23 the Medical Record Keeping Course to the Board within one year of the effective date of the
24 Decision and Order. This condition shall be monitored by the Probation Department.

25 **D. FAILURE TO COMPLY**

26 If Respondent fails to enroll, participate in, or successfully complete the educational
27 program(s) or course(s), described in conditions B and C, within the designated time period,
28 Respondent shall receive and comply with a notification from the Board or its designee to cease

1 the practice of medicine within three (3) calendar days after being so notified. Respondent shall
2 not resume the practice of medicine until enrollment or participation in the educational
3 program(s) or course(s) has been completed as required by the express language of the Decision
4 and Order. In addition, failure to successfully complete the education program(s) or course(s)
5 outlined above shall also constitute unprofessional conduct and is grounds for further immediate
6 disciplinary action.

7 ///

8 ///

9 ///

10 ///

11 ///

12 ///

13 ///

14 ///

15 ///

16 ///

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///


27 ///

28 ///


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Ian A. Scharg. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: 8/9/21 
AZIZULAH KAMALI, M.D.
Respondent


I have read and fully discussed with Respondent Azizulah Kamali, M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: 8/9/21 
IAN A. SCHARG, ESQ.
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: 8-9-21

Respectfully submitted,
ROB BONTA
Attorney General of California
STEVEN D. MUNI
Supervising Deputy Attorney General

JOHN S. GATSCHET
Deputy Attorney General
Attorneys for Complainant

SA2020302775
35356895.docx

Exhibit A

Accusation No. 800-2018-042334

1 XAVIER BECERRA
Attorney General of California
2 STEVEN D. MUNI
Supervising Deputy Attorney General
3 JOHN S. GATSCHET
Deputy Attorney General
4 State Bar No. 244388
California Department of Justice
5 1300 I Street, Suite 125
P.O. Box 944255
6 Sacramento, CA 94244-2550
Telephone: (916) 210-7546
7 Facsimile: (916) 327-2247

8 *Attorneys for Complainant*

9
10 **BEFORE THE**
11 **MEDICAL BOARD OF CALIFORNIA**
12 **DEPARTMENT OF CONSUMER AFFAIRS**
13 **STATE OF CALIFORNIA**

14 In the Matter of the Accusation Against:

15 **Azizulah Kamali, M.D.**
16 1947 N. California St., Ste. A
Stockton, CA 95204-6029

17 Physician's and Surgeon's Certificate No. A 40135,
18 Respondent.

Case No. 800-2018-042334

A C C U S A T I O N

19
20 **PARTIES**

21 1. William Prasifka ("Complainant") brings this Accusation solely in his official
22 capacity as the Executive Director of the Medical Board of California, Department of Consumer
23 Affairs ("Board").

24 2. On or about July 18, 1983, the Medical Board issued Physician's and Surgeon's
25 Certificate Number A 40135 to Azizulah Kamali, M.D. ("Respondent"). The Physician's and
26 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought
27 herein and will expire on April 30, 2021, unless renewed.

28 ///

1 **JURISDICTION**

2 3. This Accusation is brought before the Board, under the authority of the following
3 laws. All section references are to the Business and Professions Code ("Code") unless otherwise
4 indicated.

5 4. Section 2227 of the Code provides, in pertinent part, that a licensee who is found
6 guilty under the Medical Practice Act may have his or her license revoked, suspended for a period
7 not to exceed one year, placed on probation and required to pay the costs of probation monitoring,
8 or such other action taken in relation to discipline as the Board deems proper.

9 5. Section 2234 of the Code, states, in pertinent part:

10 The board shall take action against any licensee who is charged with
11 unprofessional conduct. In addition to other provisions of this article, unprofessional
12 conduct includes, but is not limited to, the following:

13 (a) Violating or attempting to violate, directly or indirectly, assisting in or
14 abetting the violation of, or conspiring to violate any provision of this chapter.

15 ...

16 (c) Repeated negligent acts. To be repeated, there must be two or more
17 negligent acts or omissions. An initial negligent act or omission followed by a
18 separate and distinct departure from the applicable standard of care shall constitute
19 repeated negligent acts.

(1) An initial negligent diagnosis followed by an act or omission medically
appropriate for that negligent diagnosis of the patient shall constitute a single
negligent act.

(2) When the standard of care requires a change in the diagnosis, act, or
omission that constitutes the negligent act described in paragraph (1), including, but
not limited to, a reevaluation of the diagnosis or a change in treatment, and the
licensee's conduct departs from the applicable standard of care, each departure
constitutes a separate and distinct breach of the standard of care.

22 ...

23 **PERTINENT DRUG DEFINITIONS**

24 6. Methadone – Generic name for the drug Symoron. Methadone is a synthetic opioid.
25 It is used medically as an analgesic and a maintenance anti-addictive and reductive preparation
26 for use by patients with opioid dependence. Methadone is a Schedule II controlled substance
27 pursuant to Code of Federal Regulations Title 21 section 1308.12. It is a Schedule II controlled
28

1 substance pursuant to Health and Safety Code 11055, subdivision (c), and a dangerous drug
2 pursuant to Business and Professions Code section 4022.

3 7. Oxycodone – Generic name for Roxicodone and Oxecta. Oxycodone has a high risk
4 for addiction and dependence. It can cause respiratory distress and death when taken in high
5 doses or when combined with other substances, especially alcohol. Oxycodone is a short-acting
6 opioid analgesic used to treat moderate to severe pain. Oxycodone can also come in a long-acting
7 formulation known as Oxycontin-ER. This formulation allows for extended release of the
8 medication. Oxycodone is a Schedule II controlled substance pursuant to Code of Federal
9 Regulations Title 21 section 1308.12. Oxycodone is a dangerous drug pursuant to California
10 Business and Professions Code section 4022, and is a Schedule II controlled substance pursuant
11 to California Health and Safety Code section 11055 subdivision (b).

12 8. Hydrocodone with acetaminophen – Generic name for the drugs Vicodin, Norco, and
13 Lortab. Hydrocodone with acetaminophen is classified as an opioid analgesic combination
14 product used to treat moderate to moderately severe pain. Hydrocodone with acetaminophen is a
15 Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section
16 1308.12.¹ Hydrocodone with acetaminophen is a dangerous drug pursuant to California Business
17 and Professions Code section 4022 and is a Schedule II controlled substance pursuant to
18 California Health and Safety Code section 11055, subdivision (b).

19 9. Oxycodone with acetaminophen – Generic name for Percocet and Endocet. Percocet
20 is a short acting semi-synthetic opioid analgesic used to treat moderate to severe pain. Percocet is
21 a Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section
22 1308.12. Percocet is a dangerous drug pursuant to California Business and Professions Code
23 section 4022, and is a Schedule II controlled substance pursuant to Health and Safety Code
24 section 11055 subdivision (b).

25 ///

26 ///

27 ¹ Prior to October 6, 2014, Hydrocodone with acetaminophen was a Schedule III
28 controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.13(e).

1 **FACTUAL ALLEGATIONS**

2 **Patient 1²**

3 10. Between February 14, 2011, and July 8, 2013, Patient 1, established primary medical
4 care with Respondent. Respondent had previously treated Patient 1 while he was working as a
5 hospitalist and Patient 1 was hospitalized. During that time, Respondent treated Patient 1 on a
6 regular basis for diabetes, hypertension, and chronic pain. Patient 1 stopped coming to see
7 Respondent following the visit on July 8, 2013.

8 11. On October 5, 2017, Patient 1 returned to Respondent's office for treatment for a new
9 diagnosis of bullous pemphigoid. Patient 1 had prior poor compliance with taking medications,
10 was taking excessive analgesics, and he was drinking heavily when he returned to Respondent's
11 care. Respondent prescribed 60 tablets of 60 mg OxyContin for pain, which was then refilled
12 monthly. While Respondent documented a history and physical examination prior to restarting
13 Patient 1's chronic pain therapy, Respondent failed to entertain non-opioid therapies, failed to
14 document discussing the risks and benefits of opioid therapy, and failed to establish monitoring
15 for misuse despite Patient 1's history of alcohol abuse. On or about February 2, 2018,
16 Respondent received notification that Patient 1, who had been living in an assisted living facility,
17 had been hospitalized in a behavioral health unit and the medical staff were requesting a referral
18 to a psychiatrist. The medical staff noted that Patient 1 was, "no longer able to self-medicate
19 properly."

20 12. On or about February 2, 2018, Respondent saw Patient 1 in his clinic. Respondent
21 documented that Patient 1 would not receive OxyContin or methadone any further. Respondent
22 prescribed Patient 1, 120 tablets of 10/325 mg Norco for pain to be taken QID. On or about
23 February 5, 2018, Respondent increased the frequency of the prescription for 10/325 mg tablets
24 of Norco to be taken every four hours. On or about February 26, 2018, Respondent changed
25 Patient 1's prescription to 60 tablets of 10/325 mg Percocet for pain after Patient 1 was released
26 after a hospitalization for pancreatitis. On or about April 9, 2018, Respondent added 90 tablets of

27 _____
28 ² In order to promote confidentiality and protect privacy, all witness identifying
information has been removed. All witnesses will be fully identified in discovery.

1 5/325 mg Percocet to be taken for breakthrough pain to Patient 1's 60 tablet of 10/325 mg
2 prescription. On or about April 16, 2018, Respondent increased Patient 1's prescription for
3 10/325 mg Percocet to 90 tablets. Patient 1 stopped seeking treatment from Respondent
4 following the April 16, 2018, visit.

5 13. Between October 5, 2017, and April 16, 2018, Respondent failed to develop and/or
6 document developing a treatment plan with pain management objectives for Patient 1.
7 Respondent failed to revisit and/or document that he revisited the treatment plan and he failed to
8 make modifications despite Respondent repeatedly changing Patient 1's chronic pain
9 medications. Between October 5, 2017, and April 16, 2018, Respondent failed to provide and/or
10 document that he provided Patient 1 with informed consent regarding the potential risks and
11 benefits of long term opioid therapy, the risk of drug interactions, the risk of respiratory
12 depression, and the limited evidence as to the benefit of long-term opioid therapy. Between
13 October 5, 2017, and April 16, 2018, Respondent failed to counsel and/or document that he
14 counseled the patient and his caregivers on the signs of opiate overdose and opiate risks.

15 14. Between October 5, 2017, and April 16, 2018, Respondent failed to perform and/or
16 document that he performed on-going patient assessments on how Patient 1 was progressing
17 towards his chronic pain treatment objectives while on opioid therapy and whether there was any
18 evidence of risks, such as overdose or diversion. Between October 5, 2017, and April 16, 2018,
19 Respondent failed to monitor and/or document that he monitored Patient 1's compliance with
20 opioid pain therapy through either reviewing Patient 1's CURES prescriptions, having Patient 1
21 provide urine drug screening, or by doing pill counting.

22 Patient 2

23 15. On November 1, 2016, Patient 2 established care with Respondent. Patient 2 had a
24 chief complaint of chronic pain syndrome caused by chronic back pain due to L5-S1
25 radiculopathy. Respondent documented that Patient 2 was taking methadone and that he had
26 enough medication to last until January 2017. Respondent performed a history and physical.
27 Respondent documented that Patient 2 would return to his clinic in January 2017.

28

1 16. On or about December 20, 2016, Patient 2 returned to Respondent's clinic.
2 Respondent documented that Patient 2 was present for a check-up and that he was still suffering
3 from chronic pain caused by his L5-S1 vertebra and he had central disc herniation. The
4 Respondent prescribed a monthly prescription of 90 tablets of 10 mg. methadone, which was a
5 continuation of Patient 2's previous prescription. The Respondent did not document why Patient
6 2 needed a prescription in December 2016, despite previously documenting that Patient 2 would
7 need a prescription in January 2017. On or about December 13, 2016, the Respondent obtained a
8 urine drug screen from Patient 2 and the result of the urine drug screen indicated that Patient 2
9 was taking methadone as prescribed. Between January 12, 2017, and December 15, 2017,
10 Respondent saw Patient 2 in clinic on a semi-regular basis. Visits were often monthly, but
11 sometimes two to three months elapsed between encounters.

12 17. Between December 20, 2016, and December 15, 2017, Respondent failed to
13 formulate and/or document that he formulated a treatment plan. In response to a series of typed
14 questions presented to Respondent on or about April 1, 2020, by the Medical Board, Respondent
15 stated he did not develop a treatment plan while treating Patient 2. Between December 20, 2016,
16 and December 15, 2017, Respondent failed to obtain and/or document that he obtained informed
17 consent from Patient 2 related to the benefits and potential risks of long-term opioid therapy,
18 including the risks of over-sedation, respiratory depression, risk of misuse and overdose.

19 18. Between December 20, 2016, and December 15, 2017, Respondent failed to obtain
20 and/or document that he obtained a pain management agreement with Patient 2. In response to a
21 series of typed questions presented to Respondent on or about April 1, 2020, by the Medical
22 Board, Respondent stated he did not obtain a pain management agreement with Patient 2.
23 Between December 20, 2016, and December 15, 2017, Respondent failed to counsel Patient 2 and
24 his caregivers on the risk of overdose and provide instruction on the safe administration of
25 naloxone. Between December 20, 2016, and December 15, 2017, Respondent failed to perform
26 and/or document that he performed an on-going patient assessment of Patient 2's progress on
27 chronic pain management including noting evidence of Patient 2's progress towards treatment
28 objectives and/or noting the absence of adverse events such as overdose or diversion. Finally,

1 between December 20, 2016, and December 15, 2017, Respondent failed to adequately document
2 and/or monitor Patient 2's compliance with his pain management regimen. While Respondent
3 did order one urine drug screen in late 2016, Respondent failed to order additional drug screens,
4 check with the CURES prescribing database, or conduct pill counts in order to monitor Patient 2's
5 compliance with his pain management regimen.

6 **FIRST CAUSE FOR DISCIPLINE**

7 **(Repeated Negligent Acts)**

8 19. Respondent's license is subject to disciplinary action under section 2234, subdivision
9 (c), of the Code in that he committed repeated negligent acts during the care and treatment of
10 Patients 1 and 2. The circumstances are as follows:

11 20. Complainant realleges paragraphs 10 through 18, and those paragraphs are
12 incorporated by reference as if fully set forth herein.

13 21. Respondent committed the following negligent acts during the care and treatment of
14 Patients 1 and 2:

15 a) By failing to appropriately perform and/or document performing a risk stratification for
16 Patient 1 prior to prescribing controlled substances;

17 b) By failing to develop and/or document developing a treatment plan with pain
18 management objectives, goals, and "exit strategy" for Patient 1;

19 c) By failing to obtain and/or document obtaining informed consent from Patient 1 for
20 long-term opioid therapy;

21 d) By failing to discuss and/or document discussing overdose risk and response with
22 Patient 1 and Patient 1's caregivers during long-term opioid therapy;

23 e) By failing to assess and/or document assessing Patient 1's response to long-term opioid
24 therapy on an on-going basis;

25 f) By failing to properly perform and/or document performing compliance monitoring of
26 Patient 1's progress on long-term opioid therapy;

27 g) By failing to develop and/or document developing a treatment plan with pain
28 management objectives, goals, and "exit strategy" for Patient 2;

- 1 h) By failing to obtain and/or document obtaining informed consent from Patient 2 for
- 2 long-term opioid therapy;
- 3 i) By failing to enter into a pain management agreement and/or document entering into a
- 4 pain management agreement with Patient 2 prior to prescribing long-term opioid therapy;
- 5 j) By failing to discuss and/or document discussing overdose risk and response with Patient
- 6 2 and Patient 2's caregivers during long-term opioid therapy;
- 7 k) By failing to assess and/or document assessing Patient 2's response to long-term opioid
- 8 therapy on an on-going basis; and,
- 9 l) By failing to properly perform and/or document performing compliance monitoring of
- 10 Patient 2's progress on long-term opioid therapy.

11 **SECOND CAUSE FOR DISCIPLINE**

12 **(General Unprofessional Conduct)**

13 22. Respondent's license is subject to disciplinary action under section 2234 in that he

14 committed general unprofessional conduct during the care and treatment of Patients 1 and 2. The

15 circumstances are as follows:

16 23. Complainant realleges paragraphs 10 through 18, and those paragraphs are

17 incorporated by reference as if fully set forth herein.

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate Number A 40135, issued to Azizulah Kamali, M.D.;
2. Revoking, suspending or denying approval of Azizulah Kamali, M.D.'s authority to supervise physician assistants and advanced practice nurses;
3. Ordering Azizulah Kamali, M.D., if placed on probation, to pay the Board the costs of probation monitoring; and
4. Taking such other and further action as deemed necessary and proper.

DATED: OCT 21 2020



WILLIAM PRASIFKA
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

SA2020302775
34334112.docx